TYK Medicines Inc. has synthesized cyclin-dependent kinase 4 (CDK4) inhibitors designed for use in the treatment of cancer, infections, and metabolic, inflammatory cardiovascular and inflammatory disorders.
Shandong Xiansheng Maidejin Biological Pharmaceutical Co. Ltd. has prepared and tested cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer.
Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged cyclin-dependent kinase 2 (CDK2) and/or CDK4 and/or CDK6 inhibitors reported to be useful for the treatment of inflammatory disorders, immunological disorders and cancer.
Avenzo Therapeutics Inc. has gained IND clearance from the FDA for AVZO-023 (formerly ARTS-023), a CDK4-selective inhibitor. The company also announced it has exercised its exclusive option for AVZO-023 from Allorion Therapeutics Inc., securing global (excluding Greater China) development, manufacturing and commercialization rights.
Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic diseases, cardiovascular, inflammatory and immunological disorders.
Insilico Medicine Inc. has disclosed substituted thiazole compounds acting as cyclin-dependent kinase (CDK) inhibitors potentially useful for the treatment of cancer.
Beigene Co. Ltd. has presented data on a CDK4 selective inhibitor, BGB-43395, for the potential treatment of this cancer type and which would reduce the neutropenia associated with CDK6 inhibition.
Pfizer Inc. has presented preclinical data on its first-in-class, selective cyclin-dependent kinase 4 (CDK4) inhibitor compound, PF-07220060, that has shown 20-fold and 4-fold increased selectivity for CDK4 vs. CDK6 compared to palbociclib and abemaciclib/ribociclib, respectively.
